GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
D

DongKook Life Science Co 303810.KQ · KRW

N/A · KOSDAQ · 🇰🇷 South Korea

Compare

1,822

-2.04%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩130.34bn

FY2022FY2025

Net income

₩8.66bn

FY2022FY2025

Free cash flow

−₩5.26bn

FY2022FY2025

Shareholders' equity

₩131.37bn

FY2022FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022
Revenue₩130.34bn₩131.82bn₩120.16bn₩107.23bn
Gross profit₩33.00bn₩28.59bn₩25.26bn₩22.19bn
Research and development₩1.92bn₩1.47bn₩1.14bn₩1.01bn
Operating income₩13.05bn₩11.67bn₩8.53bn₩6.23bn
Net income₩8.66bn₩2.24bn₩4.17bn₩4.24bn
Diluted earnings per share270.7070.18130.28132.55

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022
Total assets₩217.63bn₩191.66bn₩179.13bn₩164.43bn
Total liabilities₩86.26bn₩86.43bn₩110.42bn₩99.31bn
Debt₩3.69bn₩22.40bn₩18.75bn₩25.00bn
Shareholders' equity₩131.37bn₩105.22bn₩68.70bn₩65.13bn
Shares outstanding32m32m32m32m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022
Cash from operations₩433.6m₩11.54bn−₩4.61bn−₩2.92bn
Capital spending−₩5.69bn−₩5.08bn−₩4.79bn−₩17.38bn
Free cash flow−₩5.26bn₩6.45bn−₩9.40bn−₩20.30bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024
Revenue₩24.26bn₩33.08bn₩30.97bn₩29.44bn₩34.89bn₩35.05bn₩31.80bn
Gross profit₩4.51bn₩8.80bn₩7.39bn₩9.07bn₩8.53bn₩8.00bn₩7.39bn
Operating income₩21.9m₩3.44bn₩1.77bn₩4.28bn₩3.21bn₩3.10bn₩2.44bn
Net income−₩887.9m₩2.31bn₩1.15bn₩2.41bn₩2.85bn₩2.25bn−₩783.6m
Diluted earnings per share-27.7672.0935.8275.3989.1670.34-118.88
Cash from operations₩3.51bn₩3.04bn₩642.0m₩1.19bn₩254.0m−₩1.65bn₩11.54bn
Capital spending−₩1.66bn−₩1.50bn−₩357.0m−₩3.65bn−₩858.0m−₩826.0m−₩5.08bn
Free cash flow₩1.85bn₩1.53bn₩285.0m−₩2.46bn−₩604.0m−₩2.48bn₩6.46bn
Total assets₩217.57bn₩223.83bn₩217.63bn₩208.53bn₩206.17bn₩203.29bn₩191.66bn
Cash and short-term investments——————₩2.40bn
Debt₩3.49bn₩3.59bn₩3.69bn₩3.79bn₩22.21bn₩22.30bn₩44.51bn
Shareholders' equity₩132.70bn₩133.64bn₩131.37bn₩130.46bn₩128.11bn₩125.27bn₩105.22bn

Financial ratios

Data as of 9 Sept 2026

FY2025FY2024FY2023FY2022
Gross margin25.3%21.7%21.0%20.7%
Operating margin10.0%8.9%7.1%5.8%
Net margin6.6%1.7%3.5%4.0%
Return on equity6.6%2.1%6.1%6.5%
Return on assets4.0%1.2%2.3%2.6%
Revenue growth-1.1%9.7%12.1%—
Earnings growth285.7%-46.1%-1.7%—
Current ratio1.72x1.84x1.13x1.14x
Debt to equity0.03x0.21x0.27x0.38x
Equity ratio60.4%54.9%38.4%39.6%
Interest coverage3.45x1.46x1.71x1.72x
R&D as a share of sales1.5%1.1%0.9%0.9%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue6.9%——
Operating income27.9%——
Net income26.9%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin23.5%22.3%——

Valuation history

At each fiscal year end

FY2025
Price to earnings13.5
Price to sales0.9

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 2-for-1 split · 7 Aug 2025

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.